Mycobacterium cell wall-DNA Complex

Drug Profile

Mycobacterium cell wall-DNA Complex

Alternative Names: EN3348; MCC; MCC/HA; MCNA; Mycobacterium Cell Wall-DNA Complex/hyaluronic acid; Mycobacterium phlei cell-wall - nucleic acid complex; Prostacidin; Urocidin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioniche Life Sciences
  • Developer Bioniche Life Sciences; Endo Pharmaceuticals; ProMetic Life Sciences
  • Class Antiandrogens; Antineoplastics; DNA
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Interleukin 12 stimulants; Interleukin 6 stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bladder cancer
  • Preclinical Cancer; Infections
  • No development reported Peritoneal cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 31 Oct 2016 Telesta Therapeutics has been acquired and merged into ProMetic Life Sciences
  • 24 Aug 2016 ProMetic Life Sciences plans to acquire Telesta Therapeutics in November 2016
  • 02 Aug 2016 Telesta terminates agreement with Ipsen for MCNA program
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top